Musculoskeletal Disorders Therapeutics Market Growth, Demand, Overview and Analysis To 2020

Musculoskeletal Disorders Therapeutics Market Share and Size,
Emerging Trends, Analysis, Overview and Outlook, Growth And
Segment Forecasts To 2020
Technavio Announces the Publication of its Research Report – Global Musculoskeletal Disorder
Therapeutics Market 2016-2020
Technavio recognizes the following companies as the key players in the global musculoskeletal disorder
therapeutics market: AbbVie, Johnson & Johnson, Amgen, Pfizer, F. Hoffmann-La Roche, and Eli Lilly.
Browse full report with TOC@
Other Prominent Vendors in the market are: 3SBio, AB Sciences, AbGenomics International, Ablynx,
Adheron, Akron Molecules AG, Alder BioPharmaceuticals, Amgen Astellas BioPharma K.K. in Japan,
Ampio Pharmaceuticals, Antares Medical Services, Astellas, AstraZeneca, Baxter, Biocad, Bioiberica,
Boehringer Ingelheim, Bone Therapeutics, Can-Fite BioPharma, Celgene, Celltrion, Cellular Biomedicine,
Cerapedics, ChemoCentryx, Chugai Pharmaceutical, Coherus Biosciences, Daiichi Sankyo, Dong-A ST,
Edding Pharm, Eisai, Epirus, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gedeon
Richter, Gilead Sciences, GlaxoSmithKline, Histogenics, IBSA Institut Biochimique, iCeutica, Iltoo Pharma,
Incyte, Innovative Med Concepts, Iroko Pharmaceuticals, ISTO Technologies, KaloBios Pharmaceuticals,
KAN Research Institute, Kang Stem Biotech, Kitov Pharmaceuticals, Lexicon Pharmaceuticals, LG Life
Sciences, MEDIPOST, Medivir, Merck, Mereo, Mesoblast, MOCHIDA PHARMACEUTICAL, MorphoSys,
Morphotek, Mycenax, Neomed Institute, Novartis, Omeros, OrthoTrophix, Osteologix, OxyPharma,
PFEnex, Philogen, PhytoHealth, Plexxikon, PLx Pharma, Protalex, Proximagen, Radius Health, Regeneron
Pharmaceuticals, Samsung Bioepis, Samumed, Sandoz, Sanofi, SantoSolve AS, Steminent
Biotherapeutics, Stempeutics Research, Taiwan Liposome Company, Takeda, Tarsa Therapeutics,
Techfields Pharma, Tetec AG, TheraMAB, TiGenix, TissueGene, Tonix Pharmaceuticals, Translational
Biosciences, UCB, Vericel, Vertex Pharmaceuticals, Vitaeris, Winston Laboratories, and Zosano Pharma.
Commenting on the report, an analyst from Technavio’ s team said: “Growing focus toward abuseresistant novel drugs will be a key trend for market growth. Drug abuse is normally seen in individuals
who are on opioid therapy to treat chronic pain in musculoskeletal disorders. Pain associated with
musculoskeletal disorders are among the top causes of disability worldwide. There have been many
instances where pain therapeutics such as Vicodin, OxyContin, and Dilaudid have been prescribed
widely. This was because of the influence of pharmaceutical companies promoting their drugs for
enhanced sales. Pharma companies are under constant pressure from regulatory bodies to develop
novel abuse-resistant drugs. There is an increased need among pharma and biotech companies to
develop abuse-resistant medicinal products to treat musculoskeletal disorders with minimal or no
abuse. Off-late, researchers, and vendors are focusing on developing abuse-resistant novel drugs.”
According to the report, preference for combination therapies will be a key driver for market growth.
Combination therapies are preferred over monotherapies due to their improved efficacy. For instance,
to treat rheumatoid arthritis, more than one of the standard DMARDs is used with or without shortterm steroids. Methotrexate is given in combination with sulfasalazine or with other DMARDs.
Administering a combination of anabolic and antiresorptive agents can enhance bone density and bone
strength better than either agent given as a monotherapy. Clinical trials have been performed to
evaluate combinations of PTH1-34 or PTH1-84 with antiresorptives, including raloxifene, alendronate,
risedronate, ibandronate, zoledronic acid, and denosumab. Also, the effects of combination therapies
are site dependent. The most consistent result of combining antiresorptive drugs with PTH or
teriparatide is a greater hip BMD outcome compared with these drugs given as monotherapies. For
instance, Pfizer's Duavee combines conjugated estrogens with bazedoxifene to treat postmenopausal
osteoporosis with few side effects.
Further, the report states that multiple patent expiries will be a challenge for the market. Patent expiries
result in the loss of exclusivities of the specific drug, leading to a rapid decline in its sales. Also, the entry
of generic versions of the drugs will lead to further loss of revenue for drug manufacturers, hindering
market growth. Branded biologics, such as Humira, Enbrel, and Remicade, are set to lose their patent
exclusivities during the forecast period. For instance, Roche's Rituxan lost its patent protection in 2013
in Europe, and is set to lose the same in December 2015 in the US. These biological products, with global
sales of over $20 billion, will lose their patent protection by 2020, intensifying the competition to
develop their biosimilars.
The study was conducted using an objective combination of primary and secondary information
including inputs from key participants in the industry. The report contains a comprehensive market and
vendor landscape in addition to a SWOT analysis of the key vendors.
Request A Sample copy of This Report @
About Musculoskeletal Disorders
Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints,
muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back.
The pain and discomfort vary with the severity of the condition. These disorders have a wide range of
causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms
usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures
may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from
the drugs, physical therapy, and occupational therapy are also used to manage the condition.
Technavio’ s analysts forecast the global musculoskeletal disorder therapeutics market to grow at a
CAGR of 4.46% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global musculoskeletal disorder
therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue
generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal
disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic
arthritis, and fibromyalgia.
The market is divided into the following segments based on geography:
Technavio's report, Global Musculoskeletal Disorder Therapeutics Market 2016-2020, has been
prepared based on an in-depth market analysis with inputs from industry experts. The report covers the
market landscape and its growth prospects over the coming years. The report also includes a discussion
of the key vendors operating in this market.
To Get Discount On The Report @
Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)
[email protected]

According to the report, preference for combination therapies will be a key driver for market growth. Combination therapies are preferred over monotherapies due to their improved efficacy.